KO Cancer Act

Summary

Provides multi-year additional funding to the National Cancer Institute (NCI) by requiring annual appropriations for fiscal years 2026–2030 equal to 25% of NCI’s FY2022 appropriation, with those funds available until expended and added on top of other NCI resources. Directs the Department of Health and Human Services, working through the FDA, to complete a one-year study on causes of cancer drug shortages (economic drivers, supply chain failures, development/approval delays, and shortages of generics/biosimilars) and to report findings and recommendations to Congress within one year of enactment.

Key Points

• Appropriates to NCI each year (FY2026–FY2030) an amount equal to 25% of NCI's FY2022 appropriation.
• These additional funds are available until expended and are in addition to other NCI resources.
• Requires HHS, through the FDA, to study causes of cancer drug shortages and report to Congress within one year.
• Study must analyze economic drivers, supply-chain failures, development/approval delays, and generic/biosimilar shortages.
• Report must include recommendations and steps to address identified causes.
• Dollar value of the annual appropriations depends on the FY2022 NCI funding level (not a fixed sum in the bill).
• Funding is targeted to cancer research capacity at the federal level by boosting NCI resources over a five-year period.
• The study adds analytic burden to HHS/FDA but does not itself change regulatory approval standards or mandate supply-side actions.

Categories & Tags